Skip to the content

Development of disease-specific pre-clinical PCS models

Our R&D team is researching methodologies to establish the following disease models for our future clients:

  • Non-alcoholic fatty liver disease
  • Alcoholic liver disease
  • Paracetamol-induced liver toxicity
  • Idiopathic pulmonary fibrosis

Development of new PCS organ platforms

Our R&D team is researching the design of PCS platforms for our future clients to determine the efficacy of their anti-fibrotic molecules in Human cardiac tissue.

Development of enhanced performance PCS

To ensure that our clients are provided with state-of-art technologies, our R&D team are continually researching and upgrading protocols for:

  • optimisation of PCS preparation
  • enhanced PCS culture conditions
  • advancements to our PCS bioreactor hardware